[PDF] Top 20 Una Estetica del Diseño de Imagen y Sonido

... of bevacizumab 5 mg/kg q21 in 10 patients and ...5 patients in combination with carboplatin AUC2 weekly (n = 2) or AUC5 q21 (n = 6) or oral cyclofosfamide 50 mg/day (n = 5) or weekly paclitaxel (n = ... See full document

... metronomic-based chemotherapy, the damage to these vascular support cells, can poten- tially overcome the drug resistance by attacking the tumor through a “side effect” antiangiogenic approach ...lung ... See full document

... and bevacizumab in recurrent refractory ovarian cancer showed an overall response rate of 32%, with a very high rate of clinical benefit (79%), and a median PFS of ...with chemotherapy are on- ... See full document

... of patients were male (56.2%). All patients were ...of patients had a metastatic disease at diagnosis (75%) and did not show peritoneal involvement during their history ... See full document

... sixty-three patients with advanced ovarian carcinomas treated at our institution between April 1995 and July 2009 were included in this ...and chemotherapy. All patients received a ... See full document

... of bevacizumab across mul- tiple tumor ...of bevacizumab and erlotinib in platinum- resistant ovarian cancer, a prognostic association between tumor VEGF-A expression and disease progression ... See full document

... advanced epithelial ovarian cancer; BV, beva- cizumab; CA125, cancer antigen 125; CT, computed tomography; DCR, disease control rate; EC, epirubicin and cyclophosphamide; ECOG, Eastern ... See full document

... EOC patients varied across ...that patients with endometrioid type EOC had a worse OS than serous histological ...ASEOC patients in the current ...ASEOC patients. 2 Chang et al showed that ... See full document

... 315 patients with newly diagnosed epithelial ovarian ...The patients were treated in Maria Sk ł odowska-Curie Memorial Cancer Center and Institute, Gliwice Branch, between 2007 and ... See full document

... these patients, aggressive surgical procedures should be performed if the tumor could be safely resected to microscopic ...For patients follow- ing NACT who ended up with RD after IDS, their prog- nosis was ... See full document

... In cancer, growing evidence indicates that deregulation of SDC1 contributes to the development and progression of different tumor ...specific cancer types has been extensively evaluated in solid and ... See full document

... of patients, for which the selection of methodology is an important factor affecting research conclusions ...which case, the conclusions often less accurate ...with chemotherapy for the treatment of ... See full document

... with ovarian tumors compared to OSE in normal ovaries ...which ovarian surface epithelial cells from both rats and mice have been con- tinuously cultured, mimicking the constant damage and repair ... See full document

... Colorectal cancer continues to be an important public health concern, despite improvements in screening and better systemic ...colon cancer has resulted in signifi cant improvements in effi cacy ...agents. ... See full document

... our case, when we performed diagnostic laparos- copy, all the intestinal tract and omentum formed an omental cake, and the whole peritoneum was ...breast cancer was made from a peritoneal ...results, ... See full document

... additional patients were planned to receive the maximum tolerated dose (MTD) or 10 mg/kg (the highest planned ...considered dose- limiting toxicity. A total of 39 patients were treated, which ... See full document

... nine patients had abdominal cutaneous nodules, five of them being peri umbilical Sister Joseph’s ...rare case, Traiman et al . presented a patient with advanced ovarian carcinoma who refused ... See full document

... from ovarian cancer is continuously decreasing due to the improvement of surgery and ...of ovarian cancer patients is still unsatisfactory overall considering that only 30% of ... See full document

... Roussy Cancer Campus, Villejuif, France; S. Nicum, Cancer Centre, Oxford, UK; ...Leuven Cancer Institute and University Hospitals Leuven, Leuven, Belgium; ...Roussy Cancer Campus, Villejuif, ... See full document

... recurrent ovarian cancer derived greater OS benefit from the anti-angiogenesis ...to ovarian cancer pa- ...for patients according to whether bevacizumab was added to the ... See full document